IL10 and lung cancer: Through testing in independent cohorts, we show here that lung cancer patients developing severe toxicity from anti-PD-1/PD-L1 blockade had significant gaps in their B-cell profile at diagnosis, specifically affecting suppressive B-cell subsets (IL-10 + , TGF-β + or PDL-1 + ).